JPRN-UMIN000024148CompletedPhase 1
A phase I/II study of intravenous gemcitabine and nab-paclitaxel combined with intraperitoneal paclitaxel in pancreatic cancer patients with peritoneal metastasis - Phase I/II study of GnP + IP PTX
Department of Gastroenterology, The University of Tokyo0 sites53 target enrollmentStarted: January 1, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 53
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) contraindication for gemcitabine, nab-paclitaxel or paclitaxel 2) other active concomitant malignancies 3) allergy to iodine or gadolinium contrast agent 4) Blood transfusion or usege of G-CSF within 7 days before enrollment 5) past or current severe heart disease, liver cirrhosis, active GI ulcers or obstruction 6) severe complications such as interstitial pneumonitis, pulmonary fibrosis 7) uncontrollable diabetes mellitus 8) grade 3/4 of sensory neuropathy 9) active infection rather than HBV/HCV 11) pregnant or nursing women 12) judged to be unfit to participate in this study by investigators
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase I/II study of GnPipPTXJPRN-jRCTs031180095akai Yousuke44
Completed
Not Applicable
A combination phase I/II study of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancerpreviously untreated elderly non-small cell lung cancerJPRN-C000000072West Japan Oncology Group25
Completed
Not Applicable
Phase 2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancerung squamous cell carcinomaJPRN-UMIN000004833First Department of Surgery, Hamamatsu University School of Medicine25
Active, not recruiting
Phase 2
GABARNANCE TrialJPRN-jRCTs031180319Ikeda Masafumi110
Recruiting
Phase 2
Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancerBorderline Resectable Pancreatic CancerJPRN-UMIN000026858EPOC A1601/JASPAC07110